London - ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialisation and partnering, today announces its Half Yearly Report for the period ended 30 June 2020 and provides an update on significant post-period events.

Dr Kevin Cox, Non-Executive Chairman of ValiRx, commented: 'Throughout the reporting period, ValiRx experienced a number of significant changes, including changes to the Board, the management team, the underlying cost base and the long-term strategy. Having raised additional funds, the Company is now in a strong position to continue development of existing products and create a pipeline of novel compounds for further development and partnering. I look forward to working with the Board to continue building value in the Company and delivering on the mission of developing innovative medicines to improve the lives of patients.'

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contact:

Dr S J Dilly

Tel: +44 (0) 20 7073 2628

Email: suzanne.dilly@valirx.com

Web: www.valirx.com

About ValiRx

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

(C) 2020 Electronic News Publishing, source ENP Newswire